Insight journal - Company

Allergan: Partnering activity 2005-2013

Posted on 10 September 2013

Tags: , ,

Allergan announced over 70 partnering / licensing deals since 2005.

Abstracted from: Report: Partnering Agreements with Allergan 2005-2013

The number of partnering, collaborative R&D and licensing deals announced varied year on year with a decline since 2005 from a peak of 15 deals announced in 2005. There was another peak seen in 2008 but declined again with no partnering deals announced this year. This was probably due to the effects of the 2008 economic crisis making companies more selective in their deal making as budgets were squeezed.

The following figure shows the level of Allergan partnering deal announcements since 2005.

Figure 1: Allergan partnering deals 2005-2013

Allergan partnering activity by year

Source: Current Agreements, 2013

Analysis of the partnering deals shows a strong emphasis on partnerships in dermatology, genitourinary and ophthalmics diseases.

The following table provides an overview of the partnering deals announced by Allergan based on therapy area disclosed. Our report provides more detailed insight into the precise therapeutic target of each deal.

See: Report: Partnering Agreements with Allergan 2005-2013

Figure 2: Allergan partnering deals by therapy area 2005-2013

Allergan partnering by  therapy

Source: Current Agreements, 2013

Further analysis of these deals shows that Allergan has a preference for licensing, development and co-promotion deals, similar to many other top pharmaceutical or big pharma companies. Such partnering deals provide the right for Allergan to exploit the licensors technology in return for payment of upfront, development and sales, and royalty payments.

The following table provides an overview of the partnering deals announced by Allergan based on deal type disclosed.

Figure 3: Allergan partnering deals by deal type 2005-2013

Allergan partnering by type

Source: Current Agreements, 2013

When looking at stage of development at partnering deal signing, the most popular stage at signing is marketed with 21 deal announcements, followed closely by formulation stage with 9 deal announcements.

Allergan is also active in partnering at clinical trial stage deals. Such deals are of on-going importance to all top pharmaceutical companies as they seek to bolster their pipeline, fill gaps left as a result of drug candidates failing during clinical development, and ensure they have replacement products for when key drugs come off patent.

The following table provides an overview of the partnering deals announced by Allergan based on stage of development at signature.

Figure 4: Allergan partnering by stage of development 2005-2013

Allergan partnering by stage

Source: Current Agreements, 2013

Allergan has signed over 70 partnering, collaborative R&D and licensing deals since 2005. The following provides a summary of the top deals by headline value.

Figure 5: Top Allergan partnering deals by headline value 2005-2013

Allergan top partnering deals

Source: Current Agreements, 2013

Our report provides more detailed insight into the details of each deal. See: Report: Partnering Agreements with Allergan 2005-2013

Allergan partnering at Current Agreements

View all partnering deals for:

2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005

Full details on each deal can be found at CurrentAgreements (subscription required)

Or purchase report: Partnering Agreements with Allergan 2005-2013

 

More

Summary profile data for Allergan

Partnering interests for Allergan

M&A activity for Allergan

 

Available reports from Current Partnering

Report: Partnering Agreements with Allergan 2005-2013

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

 

Available resources for deal coverage for Allergan     

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Allergan company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply